UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2026
Commission File Number: 001-41773
Adlai Nortye Ltd.
c/o PO Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐
Form 40-F
CONTENT
Management Change of the Company
The board of directors (the “Board”)
of Adlai Nortye Ltd. (the “Company”) has appointed Archie Tse, M.D., Ph.D. (“Dr. Tse”) as the President of
the Company, while he continues to serve as the Head of Research and Development with effect from April 1, 2026.
Dr. Tse serves as the Head of Research and Development
since March 2024. Prior to joining the Company, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of
Research and Early Clinical Development, and Head of CMC Department of CStone Pharmaceuticals. Before that, Dr. Tse held leadership positions
in multinational companies, including MSD and Daiichi-Sankyo.
Dr. Tse earned his Doctor of Medicine degree and
his Doctor of Biochemistry and Molecular Biology degree from University of Southern California.
Dr. Tse does not have a direct or indirect material
interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Dr. Tse does not have any family relationship
with any directors or executive officers of the Company.
The Board has appointed Dr. Ye as the Chief Financial
Officer of the Company, while he continues to be responsible for the Company’s business development and global commercialization
strategy, with effect from April 1, 2026.
Dr. Ye serves as interim Chief Financial Officer
and Vice President of Business Development & Commercialization Strategy of the Company since January 2025. Prior to joining the Company,
Dr. Ye was the Vice President of Business Development at inVentiv Health (now Syneos Health). Additionally, Dr. Ye demonstrated leadership
in the Asia-Pacific region by managing commercial business units and establishing medical education teams for multinational pharmaceutical
companies in China. Before that, Dr Ye held leadership positions in multinational companies, including GenScript and Patheon (now part
of Thermo Fisher Scientific).
Dr. Ye holds a Bachelor of Science and a Master
of Science from Xiamen University and earned his Ph.D. at the University of Texas MD Anderson Cancer Center. His career reflects a strong
combination of scientific knowledge and strategic business leadership in the global pharmaceutical landscape.
Dr. Ye does not have a direct or indirect material
interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Dr. Ye does not have any family relationship
with any directors or executive officers of the Company.
Dr. Kaiyang Tang (“Dr. Tang”), current
President of the Company, has retired from his current position as the President of the Company with effect from April 1, 2026. The Company
will retain Dr. Tang as a Corporate Strategy Professor to the Company. Dr. Tang is committed to ensuring a smooth transition and will
continue to provide support and advice to the Company.
The Board would like to take this opportunity
to express its sincere gratitude to Dr. Tang for his valuable contributions to the Company during his tenure of service. The retirement
of Dr. Tang from the position as the President of the Company has no impact on the operations of the Company, including finance, investor
relations, and public relations, and the Company continues to conduct its operations as usual. Dr. Tang has confirmed that he has no dispute
or disagreement with the Company on any matter relating to the Company’s operations, policies, or practices and there are no matters
in relation to his resignation that need to be brought to the attention of the shareholders of the Company.
Forward-Looking and Cautionary Statements
This announcement contains forward-looking statements.
These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates,” “potential,”
“continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not
historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management
in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.
The Company may also make written or oral forward-looking
statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other
written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve
inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed
or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s
preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic
candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results
will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the
timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s
therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability
of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model
and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain
for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual
property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability
to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United
States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All
information provided in this announcement is as of the date of this announcement, and the Company does not undertake any obligation to
update any forward-looking statement, except as required under applicable law.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
Adlai Nortye Ltd. |
| |
|
| |
By : |
/s/ Yang Lu |
| |
Name: |
Yang Lu |
| |
Title : |
Chief Executive Officer and
Chairman of Board of Directors |
Date: April 1, 2026
